Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2306
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
01
Overview
DHNP-2306 is a small molecule analgesic candidate currently in the preclinical (non-clinical) stage of development by Daehan Nupharm, a South Korean pharmaceutical company. It is being developed for the management of pain, with potential applications in postoperative pain relief. As a non-narcotic analgesic, DHNP-2306 represents an effort by Daehan Nupharm to expand its portfolio into the pain management market with a focus on efficacy and safety. The drug is described in some reports as a long-acting local anesthetic, suggesting it may be designed for sustained pain control. The specific chemical structure and molecular target of DHNP-2306 have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on DHNP-2306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2306.